Invention Grant
- Patent Title: ADAMTS-13 mutant
- Patent Title (中): ADAMTS-13突变体
-
Application No.: US14166177Application Date: 2014-01-28
-
Publication No.: US08906661B2Publication Date: 2014-12-09
- Inventor: Kenji Soejima
- Applicant: The Chemo-Sero-Therapeutic Research Institute
- Applicant Address: JP Kumamoto-shi
- Assignee: The Chemo-Sero-Therapeutic Research Institute
- Current Assignee: The Chemo-Sero-Therapeutic Research Institute
- Current Assignee Address: JP Kumamoto-shi
- Agency: Oblon, Spivak, McClelland, Maier & Neustadt, L.L.P.
- Priority: JP2007-164531 20070622; JP2008-020012 20080131; JP2008-020177 20080131
- Main IPC: C12N9/48
- IPC: C12N9/48 ; C07H21/04 ; C12N9/64 ; A61K38/00
Abstract:
An enhanced disintegrin-like domain, and metalloprotease, with an isolated human thrombospondin type 1 motif, member 13 (ADAMTS-13) that includes substitutions at one or more positions in the isolated human ADAMTS-13.
Public/Granted literature
- US20140193881A1 NOVEL ADAMTS-13 MUTANT Public/Granted day:2014-07-10
Information query
